Rapid influenza testing with Cepheid XPert Flu in Emergency Department Practice

The summary for the Rapid influenza testing with Cepheid XPert Flu in Emergency Department Practice grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Assistant Secretary for Preparedness and Response, which is the U.S. government agency offering this grant.

Rapid influenza testing with Cepheid XPert Flu in Emergency Department Practice: NIH/NIAID, FDA/CDER and BARDA coordinate efforts to improve endpoints for clinical trials with new antivirals. Using endpoints originally established for clinical efficacy with oseltamivir has forced manufacturers to engage outpatient locations for enrollment of individuals with influenza-like-illness in large numbers, with very few individuals having complicated influenza that would benefit from antiviral treatment. The PHEMCE coordination has the goal to improve enrollment of high risk individuals such as those who present to the JHU Emergency Department, are identified as influenza virus positive by advanced rapid diagnostic testing, many of which are subsequently hospitalized. These patients can be treated early; thus providing a target population that can be more effectively monitored for clinical response to treatment.